WFDC2 and ovarian neoplasm: This retrospective study assessed the diagnosis value of serum HE4, CA125, ROMA, and CPH-I in patients with an ovarian tumor in early stages based on menopausal status and similar pathological subtypes, aimed at finding more accurate and effective markers for BOT and EOC.